ArticleScientific reports2026
The antibacterial effectiveness of fourth-generation poly-amidoamine dendrimers-loaded with amoxicillin in combating methicillin-resistant Staphylococcus aureus.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
In the community and in healthcare, methicillin-resistant Staphylococcus aureus (MRSA) is a major concern. Numerous infections with significant rates of morbidity and mortality are caused by MRSA strains worldwide. The widespread synthesis of virulence components is what makes MRSA so successful. The increasing resistance of MRSA to conventional antibiotics necessitates urgent exploration of alternative treatment strategies. One promising approach involves the use of fourth-generation poly-amidoamine dendrimers (PAMAM) loaded with amoxicillin, a critical β-lactam antibiotic for treating Gram-positive infections, although its efficacy is hindered by MRSA resistance. This study investigates the application of PAMAM G4 with amoxicillin to address this resistance, thereby optimizing the use of amoxicillin and potentially reducing the time and costs associated with developing new therapeutic agents. The physicochemical characteristics of the formulation were assessed through various in vitro analyses, including zetasizer and transmission electron microscopy, revealing a particle size of 219 nm, a zeta potential of -19 mV, and drug enacpsulation efficiency of 90.31%. The G4-amoxicillin dendrimer exhibited significant antibacterial activity, with a minimum inhibitory concentration of 0.25 mg/ml, as evidenced by growth assays in comparison to blank G4 and amoxicillin alone. Furthermore, the formulated nanoparticles demonstrated a substantial inhibition zone in the Kirby-Bauer Disk Diffusion method and exhibited strong anti-virulence properties, inhibiting 70% of biofilm formation and completely preventing hemolytic activity in MRSA, as shown in hemolysis assays. The formulated nanoparticles showed an effective antibacterial and anti-virulence activity against MRSA. Overall, the study added an evidence for a potential strategy to treat S. aureus and MRSA infection using nanoparticles and a potential reuse of amoxicillin.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.